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Abstract
Breast cancer is the most prevalent malignancy in women in Western countries, currently accounting for one third
of all female cancers. Familial aggregation is thought to account for 5–10 % of all BC cases, and germline mutations
in BRCA1 and BRCA2 account for less of the half of these inherited cases. In Lebanon, breast cancer represents the
principal death-causing malignancy among women, with 50 % of the cases diagnosed before the age of 50 years.
In order to study BRCA1/2 mutation spectra in the Lebanese population, 72 unrelated patients with a reported
family history of breast and/or ovarian cancers or with an early onset breast cancer were tested. Fluorescent direct
sequencing of the entire coding region and intronic sequences flanking each exon was performed.
A total of 38 BRCA1 and 40 BRCA2 sequence variants were found. Seventeen of them were novel. Seven confirmed
deleterious mutations were identified in 9 subjects providing a frequency of mutations of 12.5 %. Fifteen variants
were considered of unknown clinical significance according to BIC and UMD-BRCA1/BRCA2 databases.
In conclusion, this study represents the first evaluation of the deleterious and unclassified genetic variants in the
BRCA1/2 genes found in a Lebanese population with a relatively high risk of breast cancer.
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Introduction
In the western countries the lifetime risk of developing
breast cancer is around 12 %. About 5 %–10 % of breast
cancer (BC) and ovarian cancer (OC) are hereditary and
30 %–50 % of these are due to mutations with an auto-
somal dominant inheritance [1]. Deleterious mutations in
the BRCA1 and BRCA2 genes are the principal known
cause of hereditary BC. They are localized on chromo-
somes 17q21 and 13q12 respectively [2,3]. They are found
in 1/400-1/800 people in the general population [4-6].
For women with a personal or family history of breast
and/or ovarian cancer, BRCA1/2 full-sequencing and ana-
lysis for large genomic rearrangements (LGR) are routinely
used to quantify the genetic component of cancer risk. The
spectrum of mutations found in BRCA1/2 depends on the
studied population, ranging from few founder mutations in
some, to a wide spectrum of mutations in others [7].
In Lebanon, breast cancer remains the most frequent
type of cancer among women since 1960. In 2005, its
age adjusted incidence rate was estimated at 76 new
cases per 100.000 by the Public Health Ministry of Leba-
non and it is still increasing (http://www.public-health.
gov.lb). In France, during the same period, it was of 101
new cases per 100.000 according to the National Insti-
tute of Cancer (http://www.e-cancer.fr/). On the other
hand, the median age at diagnosis for BC in Lebanon
is 52.5 years, approximately 9 years younger than the
European/North American median [8].
Given that a woman with breast cancer is more likely
to carry a susceptibility gene mutation the younger she
is at the time of diagnosis [5,9,10], one possibility is that
the allelic frequency of high penetrance genes in the
Lebanese population may be higher than that in Cauca-
sian populations.
In order to determine the spectra and frequency of
BRCA1/2 mutations within the Lebanese population, we
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Table 1 Sequence variants identified in the BRCA1 gene
Nucleotide Change AA change Number of
patients
Clinical Relevance
(BIC)
Variation
class}
Polyphen SIFT Align
GVGD
Missense variations
250 G> T C44F* 2 Unknown 5 +++ Not tolerated Class 65
543 C>G P142A* 1 Not reported Not reported ++ Not tolerated Class 0
585 C>A L156I 1 Not reported 3 + Not tolerated Class 0
655A>G Y179C† 2 Unknown 1 +++ Not tolerated Class 45
1186A>G Q356R 19 Unknown 1 +++ Not tolerated Class 0
1575 T>C F486L† 2 Unknown 1 + Tolerated Class 0
1767A>C N550H† 2 Unknown 1 ++ Not tolerated Class 0
2196 G>A D693N 11 No effect 1 + Not tolerated Class 0
2577A>G K820E 1 Unknown 1 + Tolerated Class 0
2731 C> T P871L 47 No effect 1 + Tolerated Class 0
3232A>G E1038G 44 No effect 1 + Not tolerated Class 0
3238 G>A S1040N 2 Unknown 1 + Tolerated Class 0
3646 T>A V1176I 1 Unknown Not reported + Tolerated Class 0
3667A>G K1183R 43 No effect 1 + Tolerated Class 0
4755 G>A D1546N 1 Unknown 1 + Tolerated Class 0
4773 T>C Y1552H 1 Not reported 3 ++ Tolerated Class 0
4956A>G S1613G 45 No effect 1 + Not tolerated Class 0
5075 G>A M1652I 2 Unknown 1 + Tolerated Class 0
Nonsense mutations
5563 G>A W1815X 2 Deleterious 5
Synonyms
1964 T>C S615S 2 Not reported Not reported
2201 C> T S694S 47 No effect 1
2430 T>C L771L 45 No effect 1
4427 T>C S1436S 44 Unknown 1
5306 G>C L1729L 1 Not reported Not reported
UTRs and Intronic variations
66-67delTA 5’-UTR 29 Not reported Not reported
IVS2-91A>G 1 Not reported Not reported
IVS5 + 45 T>A 1 Not reported Not reported
IVS6 + 55 G>A 2 Not reported 3
IVS7 + 15delTTC 6 Not reported Not reported
IVS7-34 C> T 17 No effect 1
IVS8-58delT 10 No effect 1
IVS11+ 106 G>A 64 Not reported Not reported
IVS13+ 117 G>A 8 Unknown Not reported
IVS14-63 C>G 25 Not reported Not reported
IVS18+ 66 G>A 44 No effect 1
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studied a cohort of 72 Lebanese unrelated patients with
breast cancer.
Subjects and Methods
Participants
From 2001 to 2011, 72 unrelated patients were selected
to undergo sequence DNA testing for mutations in
BRCA1/2. They were referred from a wide variety of set-
tings from all over the country, ranging from private phy-
sicians’ offices to major academic medical centers,
because of elevated risk of a BRCA1/2 mutation: a per-
sonal history of invasive breast cancer and at least one of
the following criteria: A) breast cancer at any age at onset
in ≥ 2 first- and/or second-degree relatives, B) breast can-
cer <50 years in a first- or second-degree relative, C)
ovarian cancer in ≥ 2 first- and/or second-degree rela-
tives, D) breast and ovarian cancer in ≥ 2 first- and/or
second-degree relatives, E) both breast and ovarian can-
cer in a single first- or second-degree relative, F) male
breast cancer.
Two cases in men with a personal history of sporadic
breast cancer were also included.
BRCA1 and BRCA2 analysis
After an informed consent was signed, DNA was
extracted from 10 ml of peripheral blood using standard
methods [11]. All exons and> 50 bp of each flanking in-
tron were amplified in a final volume of 50 μl containing
100 ng DNA, 0.25 mM dNTPs, 100 ng of each primer
and 0.02 unit of Taq polymerase (Invitrogen Life Tech-
nologies, Carlsbad, CA, USA). PCR was performed in an
ABI9700 thermocycler (Applied Biosystems, Foster City,
CA) with initial denaturation at 94 °C for 5 min, fol-
lowed by 35 cycles of (95 °C for 30s, specific annealing
temperature for 30s, 72 °C for 30s), except for BRCA1
exons 14 and 15 where 5 cycles were added to the initial
35 cycles. Primers sequences are available on request as
well as annealing temperatures of each exon.
PCR products were purified using the illustraTM GFX
PCR DNA and Gel Band Purification Kit (GE Healthcare,
Buckinghamshire, UK), and resuspended in 40 μl of deio-
nized water. Both strands of the resultant products were
sequenced using the BigDyeW Terminator v1.1 Cycle Se-
quencing Kit (Applied Biosystems, Foster City, CA)
under standard conditions. The labeled products were
subjected to electrophoresis on an ABI3130 Genetic
Analyzer sequencing system (Applied Biosystems, Foster
City, CA, USA). Electropherograms were analyzed using
Sequence Analysis Software version 5.2 (Applied Biosys-
tems, Foster City, CA, USA) and compared to reference
sequences (BRCA1: ADNg L78833; ADNc NM_007294.3
and BRCA2: ADNg Z74739; ADNc NM_000059.3) using
ChromasPro version 1.5 (Technelysium, Queensland,
Australia). All deleterious mutations were confirmed first
on an independent second amplification and second on a
second blood specimen.
Nucleotide numbering reflects cDNA numbering with
+1 corresponding to the A of the ATG translation initi-
ation codon in the reference sequences.
The effect of missense mutations was predicted using
the BIC database (http://research.nhgri.nih.gov/bic) and
the UMD-BRCA1/BRCA2 databases and the prediction
programs: SIFT (Sorting Intolerant From Tolerant)
(http://sift.jcvi.org/www/SIFT_Blink_submit.html), Poly-
Phen (http://genetics.bwh.harvard.edu/pph/index.html),
and Align-GVGD from the International Agency for re-
search on Cancer (http://agvgd.iarc.fr) [12,13]. Predic-
tion of splicing effect was performed with MaxEntScan
using a 15 % variation threshold as proposed by Hou-
dayer et al. [14,15].
Identified variations were classified into three categories:
deleterious, unclassified variant, and neutral.
Results
The mean age at diagnosis of BC for the seventy-two
patients was 41 years old. Thirty-seven patients provided
us with their histopathological results. Thirty-one
patients had a positive estrogen-receptor (ER) and a posi-
tive progesterone-receptor (PR) disease, four patients
had a positive ER and a negative PR disease and one pa-
tient had a negative ER and a positive PR disease. Only
one patient had a triple negative disease and was not
found to have any deleterious mutation.
Within this cohort, we identified a total of 38 BRCA1
and 40 BRCA2 sequence variants, of which 17 (21.8 %)
were novel (not reported in the databases BIC and
UMD-BRCA1/BRCA2): 11 (14.1 %) in BRCA1 and 6
Table 1 Sequence variants identified in the BRCA1 gene (Continued)
IVS19-26 G>A 2 Not reported Not reported
IVS22+ 68 T>C 1 Unknown 3
c.5711 + 36 C>G 3’-UTR 1 Not reported Not reported
† Missense considered deleterious when associated.
*Missense considered deleterious.
Polyphen: +++ Variant predicted to be probably damaging, ++ Variant predicted to be possibly damaging, + Variant predicted to be benign.
UMD-BRCA1/2: 1 Variant considered neutral, 2 Variant considered likely-neutral, 3 Variant considered unclassified, 4 Variant considered likely-causal, 5 Variant
considered causal.
} in the UMD-BRCA1 database (http://www.umd.be/BRCA1/) (12) using classification system in five classes (13).
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Table 2 Sequence variants identified in the BRCA2 gene
Nucleotide Change AA change Number of
patients
Clinical Relevance
(BIC)
Variation
class}
Polyphen SIFT Align
GVGD
Frameshift mutations
5804_5808delTTAA I1859KfsX3 1 Deleterious 5
c.9485-1 G>A* 1 Not reported Not reported
Missense variations
353A>G Y42C 1 Unknown 1 +++ Tolerated Class 0
1093A>C N289H 6 No effect 1 + Not tolerated Class 0
1342A>C N372H 20 No effect 1 + Tolerated Class 0
3199A>G N991D 2 Unknown 1 ++ Tolerated Class 0
5972 C> T T1915M 2 Unknown 1 ++ Tolerated Class 0
6359 G>C G2044A 1 Unknown 3 + Tolerated Class 0
6550 C> T R2108C 1 Unknown 3 +++ Tolerated Class 0
7625 C> T A2466V 26 Unknown 1 + Not tolerated Class 0
9079 G>A A2951T 1 No effect 2 + Not tolerated Class 55
Nonsense mutations
10204A> T K3326X 1 No effect 1
Synonyms
1593A>G S455S 6 No effect 1
2457 T>C H743H 6 Unknown 1
3624A>G K1132K 16 No effect 1
4035 T>C V1269V 13 No effect 1
4791A>G L1521L 38 No effect 2
5718 C> T S1830S 1 Not reported Not reported
6741 C>G V2171V 38 Unknown 1
7470A>G S2414S 13 No effect 1
10338 G>A R3370R 1 Unknown 1
UTRs and Intronic variations
203 G>A 5’UTR 16 No effect Not reported
IVS4 + 67A>C 6 Unknown 1
IVS4 + 147 G> T 4 Not reported Not reported
IVS6 + 14 C> T 1 Unknown 3
IVS7 + 183 T>A 21 Not reported 1
IVS7-9A>G 1 Unknown Not reported
IVS8 + 56 C> T 8 Unknown 1
IVS10-34 C>A 1 Not reported 3
IVS10-51 G> T 1 Not reported 1
IVS11+ 80delTTAA 10 Unknown 3
IVS12-120 T>C 37 Not reported 3
IVS13+ 133insATTATAAAA 5 Not reported Not reported
IVS13+ 273 G>A 2 Not reported Not reported
IVS14+ 53 C> T 4 No effect Not reported
IVS16-14 T>C 25 No effect 1
IVS21-66 T>C 25 No effect 1
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(7.7 %) in BRCA2 (Tables 1 and 2). Five disease-
associated BRCA1 mutations and two disease-associated
BRCA2 mutations were found in this cohort (Figure 1).
Six out of the 38 variants found in BRCA1 (15.8 %)
were found to be of uncertain clinical significance
according to BIC and UMD. Nineteen variants were
known polymorphisms, 14 were intronic variants, 1 was
a nonsense mutation (p.W1815X), and 23 missense var-
iations (Table 1), out of which two were found of inter-
est: p.C44F and p.P142A [16,17]. The first one was
associated with a strong family history of breast
and ovarian cancer in two unrelated families and the
second one was found in a large family with many
affected women of different age of onset. One patient
presented the association of the three missense varia-
tions: p.Y179C, p.F486L and p.N550H, and one patient
the variations p.N550H and p.F486L. In 41 patients
(57 %) a haplotype presenting the combination of the fol-
lowing variations: p.S694S, p.L771L, p.P871L, p.E1038G,
p.K1183R, p.S1436S, p.S1613G and IVS18 + 66 G>A,
was found. In 9 of those, an additional variation,
p.Q356R, was found. The BRCA1 p.Y1552H variation
was the only mutation associated to the frequent haplo-
type found in our population.
Nine out of the 40 variants found in BRCA2 (22.5 %)
were of uncertain clinical significance according to BIC
and UMD databases. Twenty-three were known poly-
morphisms out of which one nonsense variation
(p.K3326X). Eighteen variants were missense variations,
19 intronic variants, and 2 frameshift mutations
(Table 2). For the latter, the first one, c.5576_5579delT-
TAA in exon 11, is a deletion of 4 bases pairs leading to
a frameshift and a stop codon three amino acids further
down (p.I1859KfsX3). This mutation was identified in a
patient diagnosed at the age of 51 years and was consid-
ered as a truncating mutation. The family history of this
individual included a breast cancer diagnosed in the
mother at 63 years. The second mutation is at position
c.9485-1 G>A leading to exon 26 skipping. It was iden-
tified in a patient diagnosed at the age of 33 years. The
family history of this individual included a breast cancer
diagnosis of the father and the paternal aunt.
Table 2 Sequence variants identified in the BRCA2 gene (Continued)
IVS22+ 53 C>G 1 Not reported Not reported
IVS24-16 T>C 1 Unknown 1
10485+ 105A>C 3’UTR 15 Not reported Not reported
*Missense considered deleterious.
Polyphen: +++ Variant predicted to be probably damaging, ++ Variant predicted to be possibly damaging, + Variant predicted to be benign.
UMD-BRCA1/2: 1 Variant considered neutral, 2 Variant considered likely-neutral, 3 Variant considered unclassified, 4 Variant considered likely-causal, 5 Variant
considered causal.
} in the UMD-BRCA1 database (http://www.umd.be/BRCA1/) (12) using classification system in five classes (13).
Figure 1 Pedigrees of the families presenting BRCA1 (A-E) and BRCA2 (F,G) mutations. Squares and circles with solid dark color indicate the
affected individuals. The dots in the squares and circles with solid dark color indicate the affected individuals.
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No variant was predicted to affect splicing except the
BRCA2 c.9485-1 G>A mutation which disrupts an ac-
ceptor splice site consensus sequence.
Discussion
In the present study, we have identified BRCA1 and
BRCA2 germline deleterious mutations in 9 carriers
among a cohort of 72 unrelated Lebanese patients with
BC, providing a frequency of mutations which repre-
sents a prevalence of 12.5 %.
The low prevalence of mutations found in our popula-
tion in comparison to other ones [5,18-20], can be
explained either by the genetic testing criteria, or by the
possibility that some mutations were missed since we
could not look for deletions or duplications of entire
exons. Consanguinity might be also an equivocal risk-
modifying factor [21,22]. Indeed, the Lebanese popula-
tion has a relatively high rate of consanguinity (around
15–20 %), and association studies on consanguinity and
breast cancer, and the frequency of BRCA1 and BRCA2
in highly consanguineous populations pointed that con-
sanguinity might lead to decreased incidence of breast
cancer [23]. Nevertheless, other studies obtained contra-
dictory results and the question remains open [23].
Our findings could not contribute in understanding
the cause of the high incidence of BC in Lebanon and
the lower age of onset observed compared to western
countries. The low age of onset was also reported in
other Asian countries, and Arab countries in the Middle
East [24-26]. It may be explained by the differences in
exposure to female hormones, diet, physical activity, or
other factors. For instance, the “Westernization” of these
populations is due to delayed childbearing, lower parity,
reduced breast-feeding, decreased exercise and dietary
changes [24]. It can lead to a ‘cohort effect’ where the
younger cohort have increased breast cancer risk com-
pared to their mothers and grandmothers, thus giving
rise to an apparent lower mean age of onset [25].
In BRCA1, a haplotype presenting the combination
of the variations: p.S694S, p.L771L, p.P871L, p.E1038G,
p.K1183R, p.S1436S, p.S1613G and IVS18 + 66 G>A
was very often found in the Lebanese population. In fact,
Dunning et al. reported a close to complete allelic asso-
ciation between the alleles at the 871, 1038 and 1613
residues [27]. Freedman et al. also reported this haplo-
type, except for the p.S694S variation, with a frequency
of 32 % [28]. The latter study found no significant differ-
ences of frequencies between patients and control
groups [28].
A major problem, the pathogenic status of several se-
quence variants that are novel or considered of un-
known clinical significance, remains unresolved. For
instance, a patient had the association of three missense
variations: p.Y179C, p.F486L and p.N550H. Taken
separately these variations were considered few years
ago non or mildly pathogenic, while this haplotype has
recently been considered to alter the protein function of
BRCA1 [29]. In another patient, two variations were
found: p.F486L and p.N550H. We considered the re-
sult as pathogenic. Analyzing the cosegregation of the
variations with the cancer phenotype within the family
can help resolving this problem, but the high cost and
the reluctance of the families to undergo the screening
prevent proceeding with this study.
To date, no other mutational analysis on breast cancer
has been conducted in Lebanon. This report helps deter-
mining the spectrum of BRCA1/2 point mutations in
our country and must be the beginning of other studies
with a larger cohort in order to determine the preva-
lence of the mutations in the general population and to
check for the existence of founder mutations given that
each of the following mutations p.C44F and p.W1815X
were found twice in this cohort. It will be also interest-
ing to evaluate the differences of BRCA1/2 mutations
frequencies among women of diverse ethnicities in Leba-
non (Muslims and Christians) or more importantly,
whether ethnicity should be taken into account in
BRCA1/2 risk assessment. The answers are important
considering the eligibility for genetic testing, and the
adoption of targeted prevention strategies.
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